14 March 2025
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or the "Company")
Exercise of Options
Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has received a notice of exercise from a third party of the Company in respect of options to subscribe for 16,666 new ordinary shares of no par value each in the capital of the Company ("Ordinary Shares") (the "Option Shares") at an exercise price of 9 pence per Option Share.
Application has been made for the Option Shares, which will rank pari passu with the Company's existing Ordinary Shares, to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and that dealings in the Option Shares will commence on or around AIM at 8.00 a.m. on 19 March 2025. Following Admission, the Company's total issued share capital will consist of 442,054,809 Ordinary Shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.
Enquiries, please contact:
| Ondine Biomedical Inc. | www.ondinebio.com |
| Strand Hanson Limited (Nominated & Financial Adviser) | +44 (0)20 7409 3494 |
| RBC Capital Markets (Broker) | +44 (0)20 7653 4000 |
| Vane Percy & Roberts (Media Contact) | +44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
